{'fraction_non_alphanumeric': 0.04343105320304017, 'fraction_numerical': 0.035830618892508145, 'mean_word_length': 4.872611464968153, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In this Issue: Eur. J. Immunol. 11'12

The cover image shows CD73 expression by CD4+ T lymphocytes in patients with inflammatory bowel disease (IBD). The representative section from biopsied tissue is stained for CD4 (bright green), CD73 (red), and co-localized CD4/CD73 (yellow), with Hoechst nuclear counterstain (blue). The image is taken from the article by Doherty et al. (pp 3062–3072), where the authors determine the phenotype and function of CD73+CD4+ T lymphocytes in patients with IBD. Prevalence and activity of CD73 in peripheral and lamina propria (LP) T cells in patients before and after treatment was measured, and the in vitro phenotype and characteristics of these cells was also assessed. The authors conclude that the CD73+CD4+ T-cell population in IBD patients is enriched with Th17 phenotype cells, and CD73 could be used as a phenotypic marker to monitor the disease activity during the treatment.